[Treatment option for pT3 patient after radical prostatectomy].

With the spread of prostate specific antigen (PSA) examination, radical cure treatment by radical prostatectomy has increased rapidly and the survival rate is high. However, about 26-68% of disease of clinical stage cT1-2 are diagnosed as pT3 in postoperative pathology. Although the 5-year PSA nonrecurrence rate is 91-97% for pT1-2, that for pT3 aN0 and pT3 bN0 is 76% and 37-40%, respectively.